Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $485.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 37.1% to $485.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 15.73% year-over-year, with the annual reading at $485.6 million for FY2025, 37.1% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $485.6 million at Theravance Biopharma, up from $415.5 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $763.5 million in Q3 2022, with the low at $343.6 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $428.2 million, with a median of $392.6 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity surged 89.4% in 2022, then plummeted 45.83% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $374.8 million in 2021, then skyrocketed by 62.05% to $607.4 million in 2022, then tumbled by 37.11% to $382.0 million in 2023, then fell by 7.29% to $354.2 million in 2024, then surged by 37.1% to $485.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $485.6 million, $415.5 million, and $426.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.